An Open-Label Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC) After PD1/PD-L1 Immune Checkpoint Inhibitors
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 04 Jun 2024 Results(n=95), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 05 May 2024 This trial has been completed in France (Global end date: 30 Apr 2024).
- 29 Apr 2024 Status changed from active, no longer recruiting to completed.